BACKGROUND: The cancer stem cell (CSC) hypothesis posits that deregulated neural stem cells (NSCs) form the basis of brain tumors such as glioblastoma multiforme (GBM). GBM, however, usually forms in the cerebral white matter while normal NSCs reside in subventricular and hippocampal regions. We attempted to characterize CSCs from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall. METHODS: We described isolating CSCs from a GBM involving the lateral ventricles and characterized these cells with in vitro molecular biomarker profiling, cellular behavior, ex vivo and in vivo techniques. RESULTS: The patient's MRI revealed a heterogeneous mass with associated edema, involving the left subventricular zone. Histological examination of the tumor established it as being a high-grade glial neoplasm, characterized by polygonal and fusiform cells with marked nuclear atypia, amphophilic cytoplasm, prominent nucleoli, frequent mitotic figures, irregular zones of necrosis and vascular hyperplasia. Recurrence of the tumor occurred shortly after the surgical resection. CD133-positive cells, isolated from the tumor, expressed stem cell markers including nestin, CD133, Ki67, Sox2, EFNB1, EFNB2, EFNB3, Cav-1, Musashi, Nucleostemin, Notch 2, Notch 4, and Pax6. Biomarkers expressed in differentiated cells included Cathepsin L, Cathepsin B, Mucin18, Mucin24, c-Myc, NSE, and TIMP1. Expression of unique cancer-related transcripts in these CD133-positive cells, such as caveolin-1 and -2, do not appear to have been previously reported in the literature. Ex vivo organotypic brain slice co-culture showed that the CD133+ cells behaved like tumor cells. The CD133-positive cells also induced tumor formation when they were stereotactically transplanted into the brains of the immune-deficient NOD/SCID mice. CONCLUSIONS: This brain tumor involving the neurogenic lateral ventricular wall was comprised of tumor-forming, CD133-positive cancer stem cells, which are likely the driving force for the rapid recurrence of the tumor in the patient.
BACKGROUND: The cancer stem cell (CSC) hypothesis posits that deregulated neural stem cells (NSCs) form the basis of brain tumors such asglioblastoma multiforme (GBM). GBM, however, usually forms in the cerebral white matter while normal NSCs reside in subventricular and hippocampal regions. We attempted to characterize CSCs from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall. METHODS: We described isolating CSCs from a GBM involving the lateral ventricles and characterized these cells with in vitro molecular biomarker profiling, cellular behavior, ex vivo and in vivo techniques. RESULTS: The patient's MRI revealed a heterogeneous mass with associated edema, involving the left subventricular zone. Histological examination of the tumor established it as being a high-grade glial neoplasm, characterized by polygonal and fusiform cells with marked nuclear atypia, amphophilic cytoplasm, prominent nucleoli, frequent mitotic figures, irregular zones of necrosis and vascular hyperplasia. Recurrence of the tumor occurred shortly after the surgical resection. CD133-positive cells, isolated from the tumor, expressed stem cell markers including nestin, CD133, Ki67, Sox2, EFNB1, EFNB2, EFNB3, Cav-1, Musashi, Nucleostemin, Notch 2, Notch 4, and Pax6. Biomarkers expressed in differentiated cells included Cathepsin L, Cathepsin B, Mucin18, Mucin24, c-Myc, NSE, and TIMP1. Expression of unique cancer-related transcripts in these CD133-positive cells, such ascaveolin-1 and -2, do not appear to have been previously reported in the literature. Ex vivo organotypic brain slice co-culture showed that the CD133+ cells behaved like tumor cells. The CD133-positive cells also induced tumor formation when they were stereotactically transplanted into the brains of the immune-deficient NOD/SCIDmice. CONCLUSIONS: This brain tumor involving the neurogenic lateral ventricular wall was comprised of tumor-forming, CD133-positive cancer stem cells, which are likely the driving force for the rapid recurrence of the tumor in the patient.
Authors: S G M Piccirillo; R Combi; L Cajola; A Patrizi; S Redaelli; A Bentivegna; S Baronchelli; G Maira; B Pollo; A Mangiola; F DiMeco; L Dalprà; A L Vescovi Journal: Oncogene Date: 2009-03-16 Impact factor: 9.867
Authors: Steven M Pollard; Koichi Yoshikawa; Ian D Clarke; Davide Danovi; Stefan Stricker; Roslin Russell; Jane Bayani; Renee Head; Marco Lee; Mark Bernstein; Jeremy A Squire; Austin Smith; Peter Dirks Journal: Cell Stem Cell Date: 2009-06-05 Impact factor: 24.633
Authors: Ty W Abel; Cara Clark; Brian Bierie; Anna Chytil; Mary Aakre; Agnieszka Gorska; Harold L Moses Journal: Mol Cancer Res Date: 2009-05-12 Impact factor: 5.852
Authors: Walid S Kamoun; Carsten D Ley; Christian T Farrar; Annique M Duyverman; Johanna Lahdenranta; Delphine A Lacorre; Tracy T Batchelor; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Dai Fukumura; A Gregory Sorensen; Rakesh K Jain Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Agnieszka K Witkiewicz; Abhijit Dasgupta; Federica Sotgia; Isabelle Mercier; Richard G Pestell; Michael Sabel; Celina G Kleer; Jonathan R Brody; Michael P Lisanti Journal: Am J Pathol Date: 2009-05-01 Impact factor: 4.307
Authors: Xuelian Chen; Qin Wen; Andres Stucky; Yunjing Zeng; Shengjia Gao; William G Loudon; Hector W Ho; Mustafa H Kabeer; Shengwen Calvin Li; Xi Zhang; Jiang F Zhong Journal: Carcinogenesis Date: 2018-07-03 Impact factor: 4.944
Authors: Long T Vu; Vic Keschrumrus; Xi Zhang; Jiang F Zhong; Qingning Su; Mustafa H Kabeer; William G Loudon; Shengwen Calvin Li Journal: PLoS One Date: 2015-03-16 Impact factor: 3.240